

1.0.7 DOC EIA

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

EQUALITY IMPACT ASSESSMENT

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Ulcerative Colitis

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Checking for updates and scope: before scope consultation (to be completed by the Developer and submitted with the draft scope for consultation)

1.1 Have any potential equality issues been identified during the check for an update or during development of the draft scope, and, if so, what are they?

Not applicable.

1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee? For example, if population groups, treatments or settings are excluded from the scope, are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

Not applicable.

1.0.7 DOC EIA

--

Completed by Developer _____

Date _____

Approved by NICE quality assurance lead _____

Date _____

2.0 Checking for updates and scope: after consultation (to be completed by the Developer and submitted with the revised scope)

2.1 Have any potential equality issues been identified during consultation, and, if so, what are they?
--

This update was not scoped.

2.2 Have any changes to the scope been made as a result of consultation to highlight potential equality issues?

This update was not scoped.

1.0.7 DOC EIA

2.3 Is the primary focus of the guideline a population with a specific disability-related communication need?

If so, do the key messages for the public need to be produced in an alternative version?

If so, which alternative version is recommended?

The alternative versions available are:

- large font or audio versions for a population with sight loss
- British Sign Language videos for a population deaf from birth
- 'Easy read' versions for people with learning disabilities or cognitive impairment.

Does an alternative version(s) of the consultation documents also need to be produced?

The focus of this guideline is not a population with a specific disability related communication need.

Updated by Developer _____

Date _____

Approved by NICE quality assurance lead _____

Date _____

1.0.7 DOC EIA

3.0 Guideline development: before consultation (to be completed by the Developer before consultation on the draft guideline)

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No issues were identified.

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

The committee noted that people with arthritis and other physical conditions find difficulty in using topical preparations of aminosalicylates or corticosteroids. The committee noted that the recommendations made allow these people to consider the use of other non-topical preparations.

3.3 Have the Committee's considerations of equality issues been described in the guideline for consultation, and, if so, where?

In the other factors the committee took into account section.

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No recommendations make it more difficult for a specific group to access services.

1.0.7 DOC EIA

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 or 3.3, or otherwise fulfil NICE's obligation to advance equality?

No barriers were identified.

Completed by Developer __C. Carmona_____

Date____09/05/2018_____

Approved by NICE quality assurance lead ____Kay Nolan _____

Date_____19 March 2019_____

1.0.7 DOC EIA

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No additional equality issues were raised by stakeholders.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Only minor changes have been made to the recommendations relating to the safe use of corticosteroids. They have no adverse impact on service access.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

There is no potential for differential impact in the recommendations.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.1, 4.2 and 4.3, or otherwise fulfil NICE's obligations to advance equality?

None.

1.0.7 DOC EIA

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

The committees discussions are reflected in the rationale and impact section of the guideline and in the committee discussion sections of the evidence reviews.

Updated by Developer _____ Chris Carmona _____

Date _____ 28 March 2019 _____

Approved by NICE quality assurance lead _____ Kay Nolan _____

Date _____ 19 March 2019 _____

1.0.7 DOC EIA